Pegferon180 mcg/0.5 ml

Pegferon is a pegylated (long-acting) form of interferon alfa-2a used for the following established indications:

FDA-approved / established uses

• Chronic Hepatitis C (CHC): In adults and pediatric patients (5 years and older) with compensated liver disease, Pegferon is used in combination with other antiviral drugs (historically ribavirin) as part of a combination regimen.
• Chronic Hepatitis B (CHB): In adults and pediatric patients (3 years and older) with HBeAg-positive or HBeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication and liver inflammation, Pegferon may be used as monotherapy.

Important note on current practice

In most settings, interferon-based regimens for hepatitis C have been largely superseded by direct-acting antiviral (DAA) regimens, which are better tolerated and more effective. Pegferon for hepatitis C is now generally reserved for specific situations where DAAs are unavailable, not tolerated, or not indicated. Use for hepatitis B remains an option alongside nucleos(t)ide analogues, chosen based on patient-specific factors.

Pegferon should only be prescribed and monitored by a physician experienced in the management of viral hepatitis.

Peginterferon alfa-2a [Pegylated Interferon alfa-2a] is a covalent conjugate of recombinant interferon alfa-2a (produced in Escherichia coli by recombinant DNA technology) with a branched, 40 kDa polyethylene glycol (PEG) moiety.

It is supplied as a sterile solution for subcutaneous injection, typically available in prefilled syringen/pen strengths of 135 mcg/0.5 mL and 180 mcg/0.5 mL. Each formulation contains standard pharmaceutical excipients (e.g., sodium chloride, polysorbate 80, benzyl alcohol as a preservative in some presentations, and buffering agents).

Pegferon is a biologic antiviral and immunomodulatory agent belonging to the interferon class of cytokines. Attaching a large PEG molecule to interferon alfa-2a slows its clearance from the body, allowing sustained blood levels with convenient once-weekly subcutaneous dosing, unlike conventional (non-pegylated) interferon alfa-2a, which requires more frequent dosing.

Pegferon works by modulating the body's immune response and directly interfering with viral replication, and it is used in the long-term management of selected patients with chronic viral hepatitis.

Pegferon belongs to the therapeutic class of Antiviral / Immunomodulatory agents – Pegylated Interferons.

Peginterferon alfa-2a [Pegylated Interferon alfa-2a] exerts its effects through binding to specific type I interferon receptors on the cell surface, activating the JAK-STAT intracellular signaling pathway. This leads to:

• Antiviral effects: induction of interferon-stimulated genes that inhibit viral replication.
• Immunomodulatory effects: enhancement of cytotoxic T-lymphocyte and natural killer cell activity against virus-infected cells.
• Antiproliferative effects: inhibition of cell proliferation.

Pegylation of interferon alfa-2a reduces renal clearance and proteolytic degradation, extending its half-life to approximately 80 hours (versus a few hours for standard interferon alfa-2a), which supports once-weekly dosing and more stable serum concentrations.

Pegferon is administered by subcutaneous injection only (never intravenously or intramuscularly). Recommended steps:

• Inject into the abdomen or thigh; rotate injection sites with each dose.
• Allow the prefilled syringe/pen to reach room temperature before injecting; do not shake vigorously.
• Administer on the same day each week for consistency.
• The first injection should be given under supervision of, or with training from, a healthcare professional; patients or caregivers may self-administer subsequent doses after proper training.
• Do not use if the solution is discolored or contains particulate matter.
• Dispose of used syringes/needles in a puncture-proof sharps container.

Clinically significant interactions with Pegferon include:

• Theophylline (CYP1A2 substrates): Pegferon can inhibit CYP1A2 activity, increasing theophylline serum levels; monitor levels and adjust theophylline dose as needed.
• Methadone: Concurrent use may increase methadone exposure; monitor for signs of toxicity (e.g., sedation, respiratory depression).
• Zidovudine and other nucleoside/nucleotide analogues: Increased risk of additive hematologic toxicity (neutropenia, anemia); monitor blood counts closely.
• Didanosine and other agents associated with hepatotoxicity/pancreatitis: Avoid combination when possible due to additive risk, particularly when Pegferon is used with ribavirin.
• Ribavirin: When used in combination, ribavirin's own interaction and safety profile (including teratogenicity and hemolytic anemia) applies in addition to that of Pegferon; see Pregnancy and Lactation and Precautions sections.

Inform the prescriber of all other medicines, including over-the-counter drugs and supplements, before starting Pegferon.

Side effects of Pegferon range from very common, mild flu-like symptoms to rare but serious reactions.

Very common / common

• Flu-like symptoms: fatigue, fever, chills, headache, myalgia, arthralgia
• Injection site reactions (redness, pain, itching)
• Nausea, vomiting, diarrhea, decreased appetite
• Alopecia (hair thinning/loss)
• Insomnia, irritability
• Laboratory abnormalities: mild-to-moderate neutropenia, thrombocytopenia

Serious (see Precautions and Warnings for full detail)

• Neuropsychiatric effects including depression and suicidal ideation
• Autoimmune disorders (thyroiditis, exacerbation of psoriasis, lupus-like syndrome)
• Cardiovascular events (arrhythmia, hypotension, myocardial infarction)
• Severe bone marrow suppression
• Ophthalmologic disorders (retinopathy, retinal hemorrhage)
• Serious infections and colitis/pancreatitis

Patients should seek prompt medical attention for mood changes, unusual bleeding/bruising, vision changes, chest pain, or signs of infection while on Pegferon. See Precautions and Warnings for monitoring recommendations related to the boxed warning.

Pregnancy: Available data on Pegferon monotherapy in pregnancy are limited. Pegferon should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision. When Pegferon is used in combination with ribavirin, this combination is contraindicated in pregnancy because ribavirin causes significant birth defects and fetal death in animal studies; extreme care must be taken to avoid pregnancy in female patients and female partners of male patients during treatment and for 6 months after stopping combination therapy, with monthly pregnancy testing.

Lactation: It is not known whether Pegferon is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, a decision should be made to discontinue breastfeeding or discontinue Pegferon, taking into account the importance of treatment to the mother; a physician should be consulted before use while breastfeeding.

Boxed Warning

Alpha interferons, including Pegferon, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluation; Pegferon should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions.

Key precautions

• Neuropsychiatric: Depression, suicidal ideation/behavior, aggressive behavior, and rarely psychosis have occurred; monitor all patients for depressive symptoms throughout treatment and after discontinuation, and use with extreme caution in patients with a history of severe psychiatric illness.
• Autoimmune disorders: May cause or worsen autoimmune conditions such as thyroiditis, lupus-like syndrome, psoriasis, and rheumatoid arthritis; monitor thyroid function periodically.
• Cardiovascular disease: Use with caution in patients with a history of cardiac disease; hypotension, arrhythmia, and myocardial infarction have been reported.
• Bone marrow suppression: May cause severe cytopenias (neutropenia, thrombocytopenia, anemia); regular complete blood count monitoring is required, particularly early in treatment.
• Ophthalmologic disorders: Retinopathy, retinal hemorrhage, and optic neuropathy have been reported; a baseline eye exam is recommended, especially in patients with diabetes or hypertension.
• Hepatic decompensation: Discontinue immediately if signs of hepatic decompensation occur in cirrhotic patients.
• Pulmonary disorders, colitis, and pancreatitis: Discontinue if severe pulmonary symptoms, persistent severe abdominal pain, or signs of colitis/pancreatitis develop.
• Serious infections: May increase susceptibility to serious bacterial, viral, and fungal infections.

Pegferon should be prescribed and monitored only by physicians experienced in managing these risks.

There is limited clinical experience with Pegferon overdosage. In case of suspected overdose, discontinue the medicine and seek immediate medical attention or contact a poison control center. Management is supportive and based on the patient's clinical signs and symptoms, as there is no specific antidote for Pegferon. Do not attempt to manage a suspected overdose at home without medical guidance.

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not shake. Keep out of reach of children. Discard any unused portion; do not reuse syringes or needles.

Renal impairment

Dose adjustment is required in moderate-to-severe renal impairment (see Dosage and Administration for creatinine-clearance-based dosing of Pegferon).

Hepatic impairment

Contraindicated in decompensated liver disease; use with close monitoring in compensated cirrhosis (see Contraindications).

Elderly

Use with caution in elderly patients; age-related decline in renal function and higher likelihood of comorbidities may increase the risk of adverse effects. Careful monitoring is recommended.

Pediatric

See Pediatric Uses for age-specific indications and dosing.

Duration of Pegferon therapy depends on the indication and, for hepatitis C, the viral genotype and treatment response: typically 24 weeks for genotype 2/3 hepatitis C combination therapy, 48 weeks for genotype 1/4 hepatitis C combination therapy, and 48 weeks for chronic hepatitis B. The treating physician determines the exact duration based on virologic response and tolerability.

Peginterferon alfa-2a [Pegylated Interferon alfa-2a] belongs to the drug class of pegylated interferons (interferon alfa derivatives), a subclass of biologic antiviral/immunomodulatory agents (cytokine therapeutics).

Peginterferon alfa-2a [Pegylated Interferon alfa-2a] binds to type I interferon receptors on the surface of target cells, triggering the JAK-STAT signal transduction pathway. This activates transcription of interferon-stimulated genes, resulting in antiviral, antiproliferative, and immunomodulatory activity that helps suppress hepatitis B and C viral replication and modulate the host immune response against infected hepatocytes. The attached polyethylene glycol (PEG) moiety slows absorption and clearance, prolonging the drug's half-life and permitting once-weekly dosing compared with conventional interferon alfa-2a.

C (monotherapy); Category X when used in combination with ribavirin

Pegferon is approved for use in chronic hepatitis C in children 5 years and older (in combination with ribavirin) and chronic hepatitis B in children 3 years and older (as monotherapy), in each case with compensated liver disease. Safety and efficacy in children below these age thresholds have not been established.

Growth inhibition (reduction in height and weight percentiles) has been observed during treatment in pediatric patients; growth typically recovers after treatment ends in most children, but long-term effects on adult height are not fully known. Regular growth monitoring is recommended, and the decision to treat a child should carefully weigh the anticipated benefit against these risks.